

EDGE ARTICLE

[View Article Online](#)
[View Journal](#) | [View Issue](#)



Cite this: *Chem. Sci.*, 2021, **12**, 12181

All publication charges for this article have been paid for by the Royal Society of Chemistry

NleB/SseK-catalyzed arginine-glycosylation and enteropathogen virulence are finely tuned by a single variable position contiguous to the catalytic machinery†

Ana García-García,^a Thomas Hicks,^b Samir El Qaidi,^c Congrui Zhu,^c Philip R. Hardwidge,^c Jesús Angulo  ^{*bde} and Ramon Hurtado-Guerrero  ^{*afg}

NleB/SseK effectors are arginine-GlcNAc-transferases expressed by enteric bacterial pathogens that modify host cell proteins to disrupt signaling pathways. While the conserved *Citrobacter rodentium* NleB and *E. coli* NleB1 proteins display a broad selectivity towards host proteins, *Salmonella enterica* SseK1, SseK2, and SseK3 have a narrowed protein substrate selectivity. Here, by combining computational and biophysical experiments, we demonstrate that the broad protein substrate selectivity of NleB relies on Tyr284^{NleB/NleB1}, a second-shell residue contiguous to the catalytic machinery. Tyr284^{NleB/NleB1} is important in coupling protein substrate binding to catalysis. This is exemplified by S286Y^{SseK1} and N302Y^{SseK2} mutants, which become active towards FADD and DR3 death domains, respectively, and whose kinetic properties match those of enterohemorrhagic *E. coli* NleB1. The integration of these mutants into *S. enterica* increases *S. enterica* survival in macrophages, suggesting that better enzymatic kinetic parameters lead to enhanced virulence. Our findings provide insights into how these enzymes finely tune arginine-glycosylation and, in turn, bacterial virulence. In addition, our data show how promiscuous glycosyltransferases preferentially glycosylate specific protein substrates.

Received 25th July 2021
Accepted 12th August 2021

DOI: 10.1039/d1sc04065k
rsc.li/chemical-science

Introduction

Glycosyltransferases (GTs) are ubiquitous enzymes that transfer a sugar moiety from either sugar nucleotides or lipid phosphate sugars to small molecules, lipids, carbohydrates, small RNAs, and proteins.^{1–3} Glycosylation of proteins is generally a multi-step process in most eukaryotic organisms,³ and likely the most abundant posttranslational modification (PTM), at least in humans.³ Glycans are generally attached to proteins in four different ways – N-linked to asparagine (Asn), O-linked to the hydroxyl groups of serine (Ser) threonine (Thr), tyrosine (Tyr), or C-linked to tryptophan (Trp) and glycation.³ Each type of

protein glycosylation is initiated by one or more unique protein GTs that in turn define the different glycosylation pathways. While most of these pathways occur post-translationally, initiation of N-glycosylation and likely POMT-directed O-mannosylation occur co-translationally.^{3,4}

A rare PTM described a few years ago, arginine-glycosylation, is catalyzed by Gram-negative bacterial GTs.⁵ This unusual PTM occurs on the arginine guanidinium group, a very poor nucleophile. In *Pseudomonas* and *Neisseria* species, arginine-glycosylation is catalyzed by EarP, while in enteropathogens, it is catalyzed by the type III secretion system effectors arginine GTs NleB and SseK.^{6–9} EarP is a rhamnosyl-transferase that uniquely glycosylates the bacterial translation elongation factor P (EF-P) to activate its function and drive bacterial pathogenicity.⁶ The NleB/SseK GTs transfer GlcNAc to arginines of several mammalian proteins and to at least five bacterial proteins.^{7–12} The NleB/SseK GTs are not classified in the CAZy database (GTnc).¹³

While *C. rodentium* only encodes one NleB, most *E. coli* strains encode two NleB proteins named NleB1 and NleB2. For several years, the role of NleB2 was unclear¹⁰ until a recent publication reported that NleB2 is an arginine GT that preferably transfers glucose to RIPK1, inhibiting host protein function similarly to other NleB/SseK GTs.¹⁴ The change in sugar donor preference was attributed to Ser252^{NleB2}, which corresponds to

^aInstitute of Biocomputation and Physics of Complex Systems (BIFI), University of Zaragoza, Mariano Esquillor s/n, Campus Rio Ebro, Edificio I+D, Zaragoza, Spain. E-mail: rhurtado@bifi.es

^bSchool of Pharmacy, University of East Anglia, Norwich Research Park, Norwich, NR4 7TJ, UK

^cCollege of Veterinary Medicine, Kansas State University, Manhattan, KS, 66506, USA

^dDepartamento de Química Orgánica, Universidad de Sevilla, Sevilla, 41012, Spain. E-mail: jangulo@us.es

^eInstituto de Investigaciones Químicas (CSIC-US), Sevilla, 41092, Spain

^fCopenhagen Center for Glycomics, Department of Cellular and Molecular Medicine, School of Dentistry, University of Copenhagen, Copenhagen, Denmark

^gFundación ARAID, Zaragoza, Spain

† Electronic supplementary information (ESI) available: Supporting methodology, 9 supporting figures and 5 supporting tables. See DOI: [10.1039/d1sc04065k](https://doi.org/10.1039/d1sc04065k)






Fig. 1 Analysis of the interacting residues in the NleB1^{EPEC}–FADD^{DD} interface. (a) Multiple sequence alignment of CrNleB, NleB1^{EPEC}, NleB1^{EHEC}, SseK1^{wt}, SseK2^{wt} and SseK3^{wt}. Residues are color-coded by their degree of sequence conservation where black, grey and white colors denote identity, high similarity and dissimilarity, respectively. Shown above the NleB1^{EPEC} sequence, in gray (catalytic domain) and brown (HLH domain), are the secondary structure elements (α -helices and β -strands) based on the NleB1^{EPEC}–UDP–Mn²⁺–FADD^{DD} structure (PDB entry 6ACI¹⁹). The residues forming part of the C-terminal lid are indicated within a red box while a blue rectangle determines the five C-terminal residues. The five inverted green triangles indicate the residues in NleB GTs that are non-conserved or partly conserved with the SseK GTs and are engaged in FADD^{DD} interaction. These residues were targeted for site-directed mutagenesis in SseK1^{wt} and SseK2^{wt}. (b) Cartoon representation of the NleB1^{EPEC}–UDP–Mn²⁺–FADD^{DD}. The catalytic and HLH domains of NleB1^{EPEC} are shown in gray and brown, respectively. The FADD^{DD} is shown in cyan. Residues are shown as sticks with carbon atoms with the corresponding colors indicated above. UDP and Mn²⁺ are shown as green carbon atoms and as a pink sphere, respectively; hydrogen bond interactions are shown as dotted orange lines but only for residues interacting at the interface of the complex. The interactions with UDP and Mn²⁺ have been extensively discussed before^{16,17} and will not be further discussed.

a Gly residue in all homologous sequences.¹⁴ *CrNleB* is highly conserved in the attaching/effacing pathogens enterohemorrhagic *Escherichia coli* (EHEC) and enteropathogenic *E. coli* (EPEC) *NleB*s.¹⁵ Particularly, the identity between these enzymes is ~89% between *CrNleB* and *NleB*s, and 98% between *NleB*s (Fig. 1a). *Salmonella enterica* strains encode up to three functional *NleB* orthologs named *SseK1*, *SseK2*, and *SseK3*. When the *CrNleB*/*NleB*^{EPEC/EHEC} are compared to *SseK1/2/3*, the sequence identities drop significantly, ranging from 51 to 57% (Fig. 1a). At the structural level, these enzymes show a high degree of similarity and are built by two conserved major domains and a C-terminal lid, which is also required for the catalytic activity of the enzyme. The GT-A fold-adopting catalytic domain is the largest domain and includes the essential DxD and HEN (His–Glu–Asn) motifs. The helix-loop-helix (HLH) domain comprises two helices, α 3 and α 4, connected by a loop^{16–19} (Fig. 1a and b).

NleB GlcNAc-transferase activity is essential to bacterial virulence.⁷ Multiple host protein substrates for the *CrNleB* and *NleB*^{EPEC/EHEC} have been described and include the death domains (DD) of tumor necrosis factor receptor 1 (TNFR1), the TNFR1-associated death domain protein (TRADD), the receptor-interacting serine/threonine-protein kinase 1 (RIPK1), the TNF-receptor superfamily member 25 (DR3 or TNFRSF25), and FAS-associated death domain protein (FADD).^{9,19,20} In addition, these enzymes glycosylate other proteins non-containing DDs. *CrNleB* and *NleB*^{EHEC}, but not *NleB*^{EPEC}, glycosylate GAPDH,¹⁰ and *NleB*^{EPEC} glycosylates HIF-1 α .²¹ Overall, *NleB* disrupts TNFR-associated factor (TRAF) signaling, leading to inhibition of the pro-inflammatory NF- κ B pathway.^{7,9,10} *SseK1*, *SseK2*, and *SseK3* have a narrower protein substrate selectivity; *SseK1* glycosylates TRADD⁹ and GAPDH,¹⁰ but not FADD;¹⁰ *SseK2* glycosylates FADD¹⁰ but not TRADD¹⁷ or GAPDH;¹⁰ *SseK3* glycosylates TNFR1,¹⁸ TRAIL,¹⁸ and the small GTPase Rab1,²² but not GAPDH¹⁰ or FADD.¹⁰ This illustrates that although the *SseK* and *NleB* GTs are highly similar at the sequence and structural level, they display dissimilarities in their protein substrate selectivity. Furthermore, the *SseK* GTs are inactive towards some *NleB*-specific protein substrates.^{10,17}

To address the molecular basis of *NleB/SseK* protein substrate selectivity and to determine why some *SseK* GTs do not glycosylate particular protein substrates, we report herein a multidisciplinary approach on wild type (wt) *NleB*^{EHEC}, *SseK1*, and *SseK2*, combined with the characterization of different *SseK1* and *SseK2* mutants, which reveals that a single second-shell residue near to the catalytic machinery, finely tunes substrate selectivity and catalysis. We also show that optimal kinetic parameters are accomplished by the mutants S286Y^{SseK1} and N302Y^{SseK2}, which contain a Tyr residue that replaces *SseK1*^{wt} Ser286 and *SseK2*^{wt} Asn302. We recover full activity with S286Y^{SseK1} on FADD^{DD} and N302Y^{SseK2} on DR3^{DD}. Finally, we demonstrate that the integration of S286Y^{SseK1} and N302Y^{SseK2} mutants in a *Salmonella enterica* strain devoid of all *SseK* enzymes increases *Salmonella* survival in macrophages, suggesting that better enzymatic kinetic parameters lead to enhanced virulence.

Results and discussion

Bioinformatics and structural analysis of *NleB/SseK* GTs

To determine the molecular basis of why *SseK1*^{wt} does not glycosylate FADD^{DD}, we performed a multiple alignment analysis of *CrNleB*, *NleB*^{EPEC/EHEC}, and *SseK* GTs, and also carefully inspected the residues of *NleB*^{EPEC} engaged in recognition of FADD^{DD} (Fig. 1a and b; PDB entry 6AC1¹⁹). Fourteen *NleB*^{EPEC} residues established diverse types of interactions with FADD^{DD} residues, with salt bridge interactions being the most prevalent, followed by hydrogen bond/hydrophobic interactions (Fig. 1b and Table S1†). Five of these 14 residues were in the HLH domain (Tyr145, Glu149, Asp151, Tyr153 and Leu154), while the others (Glu253, Lys277, Asp279, Tyr283, Tyr284, Asp285, Lys289, Lys292, and Tyr303) were located in the catalytic domain (Fig. 1b and Table S1†). Interestingly, not a single residue of the C-terminal lid interacted with FADD^{DD} residues. In addition, but with the exception of Glu149, which interacted through its backbone with the Arg135^{FADD} side chain, the other residues interacted with FADD residues through their side chains. A smaller number of FADD^{DD} residues were engaged in recognition of *NleB*^{EPEC}. All these nine residues were located along α 2, α 3, α 4, and the loops connecting them (Fig. S1 and Table S1†). Again, and as found for *NleB*^{EPEC} residues, most of the FADD^{DD} residues involved in recognition of *NleB*^{EPEC} utilized their side chains. Four of these nine residues (Trp112^{FADD}, Arg117^{FADD}, Val121^{FADD}, and Ile126^{FADD}) were completely conserved between different DDs and likely comprise the minimal epitope for *NleB/SseK* GTs recognition, as suggested before.^{17,19} Note that Arg117^{FADD} is the acceptor site and is engaged in a salt bridge with the proposed catalytic base Glu253 (ref. 19) (Fig. 1b).

A thorough comparison of the grade of conservation of the *NleB*^{EPEC} fourteen interacting residues with aligned residues from other orthologs indicated that only five residues might be responsible for the null activity of *SseK1*^{wt} on FADD^{DD} (Table S1†). These residues were mostly non-conserved or partially conserved with *SseK1*^{wt} residues. Tyr145 and Glu149 were quite close in the structure and located in a loop connecting α 3 with α 4 of the HLH domain (Fig. 1b). The other three residues, Tyr284, Lys289, and Lys292, were located in the catalytic domain and exclusively in α 9 (Fig. 1a). While both Lys residues were proximal in the structure and established salt bridges with Asp123^{FADD} and Glu130^{FADD}, Tyr284 was more isolated from them and interacted through its side chain to Val121^{FADD} backbone and Ile126^{FADD} side chain (Fig. 1 and Table S1†). Tyr284 was also engaged in a CH– π interaction with the proximal Tyr283 side chain, which likely controls the interaction between the acceptor Arg117^{FADD} and the catalytic base Glu253 (Fig. 1b). Hence, Tyr284 is a second-shell residue with respect to the catalytic machinery in which Glu253 is one of the key players.

The S286Y^{SseK1} mutation switches on activity against FADD^{DD}

Based on the above analysis, we selected five residues from *NleB* GTs to perform site-directed mutagenesis on the corresponding



aligned residues in SseK1^{wt} and SseK2^{wt} . To simplify the number of mutations in SseK1^{wt} and to minimize the potential combinations among them, we established three groups of residues: the two pairs $\text{Tyr145-Glu149}^{\text{NleB1}}$, and $\text{Lys289-Lys292}^{\text{NleB1}}$, based on their proximity at structural level, and $\text{Tyr284}^{\text{NleB1}}$ as one unique and independent residue from the others.

To initiate this study, we determined the kinetic parameters of $\text{NleB1}^{\text{EHEC}}$ on UDP-GlcNAc and FADD^{DD} (see Fig. 2a, left panel, ESI, Fig. S2, and Table S2†). $\text{NleB1}^{\text{EHEC}}$ displayed a clear

substrate inhibition profile under the presence of variable concentrations of FADD^{DD} (Fig. 2a; $K_i = 793 \pm 160 \mu\text{M}$) that was not present in the other SseK2^{wt} and mutant proteins. This behavior might be attributed to a different non-productive FADD^{DD} structural arrangement under high concentrations of this substrate. On the contrary, substrate inhibition under variable concentrations of UDP-GlcNAc was barely present (Fig. S2†). The K_m s for UDP-GlcNAc and FADD^{DD} were 125 ± 33 and $13 \pm 2.5 \mu\text{M}$, respectively, and the k_{cat} was $\sim 100 \text{ min}^{-1}$ (Fig. 2b, left and middle panels, and Table S2†), a value in




Fig. 2 Enzyme kinetics and ITC experiments of $\text{NleB1}^{\text{EHEC}}/\text{SseK1}^{\text{wt}}/\text{SseK2}^{\text{wt}}$ and mutants on FADD^{DD} . (a) Glycosylation kinetics of $\text{NleB1}^{\text{EHEC}}/\text{SseK1}^{\text{wt}}/\text{SseK2}^{\text{wt}}$ and mutants against FADD^{DD} . (b) Plots comparing the K_m , k_{cat} and catalytic efficiency (k_{cat}/K_m) of the different $\text{NleB1}^{\text{EHEC}}/\text{SseK1}^{\text{wt}}/\text{SseK2}^{\text{wt}}$ and mutants. Additional kinetic data are given in Table S2.† Asterisks indicate that the kinetic parameters for SseK2^{wt} are estimated due to its poorer binding to FADD^{DD} . (c) (left) Thermodynamic dissection of the interaction of the different enzyme forms with FADD^{DD} . The binding Gibbs energy (ΔG), enthalpy (ΔH), and entropy ($-T\Delta S$) are in kcal mol^{-1} . Any negative value represents a favorable contribution to the binding, whereas a positive value represents an unfavorable contribution (right) graph depicting the K_d s of the different enzymes.



agreement with other previous reported k_{cat} values for a similar protein GT such as EarP²³ (k_{cat} of 35 min⁻¹), and an unrelated one such as PoFUT2 (ref. 24) (k_{cat} of 144 min⁻¹), both of which are glycosyltransferases that glycosylate other types of folded domains. Furthermore, these k_{cat} values also match reported k_{cat} values for unstructured peptides in the presence of other protein GTs (a range between 46–400 min⁻¹, and 18–300 min⁻¹ for different peptides using GalNAc-T3 (ref. 25) and *N*-glycosyltransferase,^{26,27} respectively). As expected from previous^{8,9} and our own studies,¹⁰ SseK1^{wt} was inactive on FADD^{DD} and SseK2^{wt} was slow on FADD^{DD} (Fig. 2a, middle and right panel, and Table S2†). Particularly, the K_m , k_{cat} , and catalytic efficiency of SseK2^{wt} were 95-, 6.7-, and 630-fold worse than those of NleB1^{EHEC} (Fig. 2b). Note that the kinetic parameters for SseK2^{wt} are estimated due to its poor binding to FADD^{DD}.

Seeking to switch on the activity of SseK1^{wt} towards FADD^{DD}, we characterized the double mutants M147Y-K151E^{SseK1} and N291K-R294K^{SseK1}, and the single mutant S286Y^{SseK1}. In all of these mutants, we replaced the SseK1^{wt} residues by the corresponding positions in NleB1^{EPEC/EHEC}. While the initial velocity of the double mutants was very slow (~46-fold worse than the NleB1^{EHEC} initial velocity at 800 μM FADD^{DD}; Fig. 2a, middle panel), strikingly, the k_{cat} for the single mutant S286Y^{SseK1} matched that of NleB1^{EHEC} (only 1.38-fold worse; Fig. 2b, middle panel), implying that with a single mutation we reached the optimal k_{cat} found for NleB1^{EHEC}. On the contrary, K_m and the catalytic efficiency for S286Y^{SseK1} were slightly worse (4.4- and 6.7-fold worse than the ones reported for NleB1^{EHEC}; Fig. 2b, left and right panels, and Table S2†). To obtain an SseK1 mutant with similar kinetic parameters as those of NleB1^{EHEC}, we combined the double mutants to generate a quadruple mutant (M147Y-K151E-N291K-R294K^{SseK1}). We further added the S286Y^{SseK1} mutation to the latter mutant generating a quintuple mutant (M147Y-K151E-S286Y-N291K-R294K^{SseK1}). Additionally, we made another mutant combining the quintuple mutant with a deletion of the C-terminal last 5 residues only found in SseK1^{wt} (Fig. 1a) named as quintuple-del mutant. The k_{cat} , K_m and catalytic efficiency for the quadruple mutant were 4.3-/2.7-, 6.1-/1.4-, and 27-/4-fold worse than the ones for NleB1^{EHEC} and S286Y^{SseK1}, respectively (Fig. 2a, b, and Table S2†). This demonstrates that the kinetic parameters of the quadruple mutant are closer to those of S286Y^{SseK1} than those of NleB1^{EHEC}. Hence, either the combination of multiple changes (quadruple mutant) or just a single mutation (S286Y^{SseK1} mutant) leading to higher affinity of SseK1 towards FADD^{DD} are two different approaches to achieve k_{cat} values close to that of NleB1^{EHEC}. The kinetic parameters of the quintuple and quintuple-del, mainly k_{cat} and k_{cat}/K_m , were highly similar to each other and very close to those of S286Y^{SseK1} (Fig. 2b, middle and right panels). However, they differed slightly more in their K_m s, with the quintuple/quintuple-del mutants K_m s being ~2-fold lower than that of S286Y (Fig. 2b, left panel). The reduction in K_m for the quintuple/quintuple-del mutants enhanced their catalytic efficiencies, approximating their values to that of NleB1^{EHEC}. Overall, the removal of the C-terminal 5 amino acids in SseK1^{wt} and the addition of 5 mutations led to an SseK1 form with the closest kinetic parameters to those of

NleB1^{EHEC}, mainly due to the lowest K_m towards FADD^{DD} of these SseK1 mutants.

Having established that a single mutation (S286Y^{SseK1}) was sufficient to achieve optimal kinetic parameters and render the best k_{cat} of all the characterized mutants, we mutated Ser286^{SseK1} and Asn302^{SseK2} to Asn/Ile, and Ser/Ile/Tyr, respectively, rendering the mutants S286N^{SseK1}, S286I^{SseK1}, N302S^{SseK2}, N302I^{SseK2} and N302Y^{SseK2}. These single mutants are derived from the alignment of Ser286^{SseK1} with Asn302^{SseK2}, Ile289^{SseK3} and Tyr284^{CrNleB/NleB1} (Fig. 1a). As expected from the previous results¹⁰ of SseK3^{wt} on FADD^{DD}, the S286I^{SseK1} and N302I^{SseK2} were completely inactive, and N302S^{SseK2} was also completely inactive on FADD^{DD}, implying that both Ser or Ile residues are likely deleterious for catalysis (Fig. 2a, middle and right panel). In addition, S286N^{SseK1} showed poor glycosylation of FADD^{DD} (~15-fold worse initial velocity than the one reported for NleB1^{EHEC} at 800 μM FADD^{DD}) as found for SseK2^{wt} (Fig. 2a, middle panel). Although N302Y^{SseK2} achieved a highly similar k_{cat} to those of NleB1^{EHEC} and S286Y^{SseK1}, its K_m towards FADD^{DD} was worse (3- and 12-fold higher than those of S286Y^{SseK1} and NleB1^{EHEC}, respectively). This caused a drop in catalytic efficiency compared to that of NleB1^{EHEC} that was more drastic than that for S286Y (3- and 20-fold worse to those of S286Y^{SseK1} and NleB1^{EHEC}, respectively; Fig. 2a, b, and Table S2†).

Overall, our data indicate that a single mutation, either from Ser286^{SseK1} or Asn302^{SseK2} to Tyr, is sufficient to switch on and improve SseK1 and SseK2 glycosylation on FADD^{DD}, respectively. This mutation allows reaching kinetic parameters very close to those of NleB1^{EHEC}.

Binding of SseK1 to FADD^{DD} is dramatically increased by the S286Y mutation

To determine the thermodynamic parameters of the mutants to FADD^{DD}, we performed isothermal titration calorimetry (ITC) experiments. First, we determined the K_d of UDP for binding to NleB1^{EHEC} in the presence of MnCl₂ ($K_d = 14.92 \pm 1.11 \mu\text{M}$) (Table S3 and Fig. S3†). Then, we evaluated whether these enzymes require UDP binding prior to binding FADD^{DD}. While in the absence of UDP, NleB1^{EHEC} or S286Y^{SseK1} did not show any binding to FADD^{DD}, this turned out to be the opposite in the presence of excess UDP (Fig. 2c, Table S3 and Fig. S3†). This provides compelling evidence that the NleB/SseK GTs likely follow an ordered bi-bi kinetic mechanism. In this mechanism, these enzymes are likely in an inactive state in the apo form (open C-terminal lid) that only shifts to the active state (closed C-terminal lid) in the presence of UDP-GlcNAc/MnCl₂. This mechanism also implies an induced-fit mechanism by UDP-GlcNAc, in which this sugar nucleotide induces the closure of the C-terminal lid leading to the active state (Fig. S4†). The induced-fit mechanism has been also proposed for unrelated glycosyltransferases such as GalNAc-T2, B4GALT1 and the lactose synthase.^{28–30}

Once we determined that FADD^{DD} binding to these enzymes requires prior UDP binding, we measured the thermodynamic parameters for all mutants *versus* FADD^{DD} under an excess of UDP. We could only get titration for NleB1^{EHEC} and the



S286Y^{SseK1}, N302Y^{SseK2}, quadruple, quintuple, and quintuplet mutants (Fig. S3†).

Detailed analysis of the thermodynamic parameters of the interaction showed that the binding of FADD^{DD} to NleB1^{EHEC} and the mutants was largely entropy-driven ($-\Delta S$), while the binding of UDP was favored by a gain in enthalpy (ΔH), with a reduced entropic component (Fig. 2c and Table S3†), implying distinct interaction behaviors between these molecules. The unique thermodynamic profile exhibited by FADD^{DD} might be due to the release of a vast number of surface water molecules from both FADD^{DD} and NleB1^{EHEC}/SseK1/SseK2 mutants upon binding, promoting a favorable desolvation entropy. On the contrary, the significant reduction in donor substrate mobility upon binding to the enzyme, along with the large number of hydrogen bonds between UDP or UDP-GlcNAc and these enzymes are largely the major factors explaining the reduction in the entropic component and the favorable enthalpy.^{17,19} Interestingly, the single mutants S286Y^{SseK1} and N302Y^{SseK2} achieve favorable binding Gibbs energy to FADD by reducing the beneficial entropy component of the interaction, what is accompanied by a more favorable enthalpy. Binding to FADD thus globally follows a pattern of enthalpy–entropy compensation where multiple mutants show similar thermodynamic profiles to that of NleB1, with single mutants benefitting from enthalpy, suggesting that the solvation/desolvation process at

the interface of interaction with FADD is more similar to NleB1 for the multiple mutants than for the single mutants (Fig. S5†).

The K_{dS} are in the low μM range except for that of N302Y^{SseK2}. Although the K_{dS} are much lower than the K_{mS} , there is some correlation between the K_{mS} and the K_{dS} : those enzymes with lower K_m values also possess lower K_{dS} (Table S3†). Again, NleB1^{EHEC} displays the highest affinity ($K_d = 0.2 \pm 0.04 \mu\text{M}$), being 3-, ~6-, 13-, and ~472-fold better than those of quintuplet-del, quintuplet/S286Y^{SseK1}, quadruplet, and N302Y^{SseK2} mutants, respectively (Fig. 2c, right panel, and Table S3†).

Overall, our data show that the improvement in binding of SseK1 mutants and N302Y^{SseK2} to FADD^{DD} is essential to promote catalysis. Strikingly, this can be achieved by a single-mutation, S286Y^{SseK1} or N302Y^{SseK2}, or by a combination of multiple mutations in different regions of the enzyme. Nevertheless, these single mutations are enough to account for the best k_{cat} of all mutants, implying that the Tyr residue in that position might also play a catalytic role.

Molecular dynamics simulations determine that the mutation S286Y^{SseK1} couples binding to catalysis

To understand the structural role of the single mutation S286Y^{SseK1} in enhancing binding and enabling glycosylation of the FADD^{DD}, we carried out Gaussian accelerated Molecular




Fig. 3 Molecular dynamics simulations of the complexes of S286Y^{SseK1} and NleB1^{EPEC} with FADD^{DD}. Superposition of MD frames (0.7, 0.8, 0.9, and 1.0 μs) of the complexes. (a and c) show the complex of FADD^{DD} with the S286Y^{SseK1} single mutant. (b and d) show the complex of FADD^{DD} with NleB1^{EPEC}. In (a and b) both proteins are in cartoon representation (enzyme in yellow, acceptor FADD^{DD} in cyan), and the side chain at the point of mutation (Tyr286^{SseK1} or Tyr284^{NleB1}) is in black sticks. (c and d) show expansions of the key residues at the interface of contact involving the catalytic domain (FADD^{DD} in cyan cartoon representation; Tyr286^{SseK1} or Tyr284^{NleB1} in black sticks; key S286Y^{SseK1} or NleB1^{EPEC} residues in yellow sticks).



Dynamics simulations (GaMD) on 3D molecular models of the complexes of $\text{NleB1}^{\text{EHEC}}$, SseK1^{wt} and mutants with UDP-GlcNAc-Mn²⁺ and FADD^{DD} (see ESI and Fig. S6†).

In the case of $\text{S286Y}^{\text{SseK1}}$, Tyr286 maintains similar favorable contacts as those in the complex of $\text{NleB1}^{\text{EPEC}}$ with FADD^{DD} (Fig. 3), where its aromatic side chain is inserted into the groove formed by helices $\alpha 2$ and $\alpha 3$ and the loop connecting them, making close contacts with the backbone of $\text{Val121}^{\text{FADD}}$ and the side chain of $\text{Ile126}^{\text{FADD}}$. However, for SseK1^{wt} and $\text{S286I}^{\text{SseK1}}$ the side chain at the point of mutation is either too small (Ser286) or too bulky (Ile286) to be properly allocated in the groove between helices $\alpha 2$ and $\alpha 3$, respectively (Fig. S7†). In the case of $\text{S286N}^{\text{SseK1}}$, the side chain is equally not well allocated in the FADD groove, although a persistent hydrogen bond with $\text{Asp123}^{\text{FADD}}$ at helix $\alpha 2$ was observed (Fig. S7†).

These GaMD simulations results correlate very well with the kinetics measurements for SseK1^{wt} and mutants, supporting a key role of the interaction of the side chain at the point of mutation with $\text{Ile126}^{\text{FADD}}$ from the FADD^{DD} $\alpha 2$ - $\alpha 3$ groove, most likely in the form of a favorable enthalpy contribution (Fig. S8†).

The GaMD simulations also allowed us to identify an important correlation between the side chain present at the point of mutation and catalysis, by analyzing the internal dynamics of the acceptor site (Arg117^{FADD} side chain). In

$\text{NleB1}^{\text{EPEC}}$, the salt-bridge interaction between the proposed catalytic base ($\text{Glu253}^{\text{NleB1}}$) and the guanidinium of $\text{Arg117}^{\text{FADD}}$ is maintained and holds the Arg117 in an orientation appropriate for the nucleophilic attack over the beta face. That interaction is not very conserved in the simulations of the other enzymes, and the role of $\text{Glu253}^{\text{NleB1}}$ ($\text{Glu255}^{\text{SseK1}}$) is replaced by the carboxylate of another residue, $\text{Asp188}^{\text{SseK1}}$, which holds the Arg117 side chain in a rather rigid proper orientation all along the simulation time. This only occurs for the mutants that show glycosylating activity, $\text{S286Y}^{\text{SseK1}}$ and $\text{S286N}^{\text{SseK1}}$, whereas that interaction is absent in the cases of $\text{S286I}^{\text{SseK1}}$ and SseK1^{wt} (Fig. S8†) where the Arg117 is more dynamic. This is reflected in the root-mean-square-fluctuations (RMSF) values of Arg117 in the complexes with $\text{NleB1}^{\text{EPEC}}$, $\text{S286Y}^{\text{SseK1}}$, and $\text{S286N}^{\text{SseK1}}$, which showed the lowest values (below 1 Å; Table S4†).

GaMD simulations also show that $\text{Phe187}^{\text{SseK1}}$, $\text{Asp188}^{\text{SseK1}}$, and $\text{Arg191}^{\text{SseK1}}$ form a stable network of interactions with $\text{Arg117}^{\text{FADD}}$ (acceptor) and the sugar nucleotide (donor, Fig. S9†). $\text{Asp188}^{\text{SseK1}}$ and $\text{Arg191}^{\text{SseK1}}$ constitute the Asp/Arg dyad present in other bacterial GTs effectors.¹⁹ These results explain the need for a GT-bound sugar nucleotide to have efficient FADD^{DD} binding (ordered bi-bi mechanism). The identified network of interactions leads to favorable contacts of the carboxylate side chain of $\text{Asp188}^{\text{SseK1}}$ with the acceptor




Fig. 4 Enzyme kinetics of $\text{NleB1}^{\text{EHEC}}$ / SseK1^{wt} / SseK2^{wt} and mutants on DR3^{DD} . (a) Glycosylation kinetics of $\text{NleB1}^{\text{EHEC}}$ / SseK1^{wt} / SseK2^{wt} and mutants against DR3^{DD} . (b) Plots comparing the K_m , k_{cat} and catalytic efficiency (k_{cat}/K_m) of the different $\text{NleB1}^{\text{EHEC}}$ / SseK1^{wt} / SseK2^{wt} and mutants. Additional kinetic data are shown in Table S5.† Asterisks indicate that the kinetic parameters for $\text{N302Y}^{\text{SseK2}}$ are estimated due to its poorer binding to DR3^{DD} .



Arg117^{FADD}, and of this with the sugar nucleotide. These interactions are conserved in NleB1-FADD^{DD} complex (Fig. S9†).

The GaMD simulations support that a single mutation on Ser286^{SseK1} to Tyr leads to a favorable coupling between increased affinity and stability of Arg117^{FADD} orientation, appropriated towards the nucleophilic attack of the anomeric carbon to render inversion of the configuration. This is achieved by a favorable interaction of the Tyr286^{SseK1} residue with Ile126^{FADD}, leading to a stable salt-bridge of the Arg117^{FADD} guanidinium polar head with the carboxylate of Asp188^{SseK1}. The fact that Glu255^{SseK1} is far away from Arg117^{FADD} and that Asp188^{SseK1} takes the role of the leading carboxylate in keeping the guanidinium on a proper orientation over the beta face of the GlcNAc residue of the donor substrate, strongly suggests

that Asp188^{SseK1} might function as the catalytic base in S286Y^{SseK1} and S286N^{SseK1} mutants. In fact, the D186A mutation in NleB1^{EPEC} (the aligned residue in NleB1) has been also reported to be detrimental for NleB1 activity.¹⁹

The N302Y^{SseK2} mutant is active against DR3^{DD}

Having established the importance of a Tyr residue in binding/catalysis at position 284 of CrNleB/NleB1^{EPEC/EPEC}, 286 of SseK1 and 302 of SseK2, we reasoned that the null activity of the SseK2^{wt} on a NleB substrate could likely be rescued by replacing Asn302 by Tyr. To achieve that, we first evaluated the activity of NleB1^{EHEC}, SseK1^{wt} and SseK2^{wt} on DR3^{DD}, finding out that while NleB1^{EHEC}, SseK1^{wt} were active on DR3^{DD}, SseK2^{wt} was not (Fig. 4a). In these experiments, the K_m , k_{cat} and the catalytic




Fig. 5 Mutations at S286 in SseK1 and N302 in SseK2 impact *Salmonella* abundance in RAW264.7 cells. RAW 264.7 cells were infected with the indicated *Salmonella* complementation strains at a multiplicity of infection of 10. Colony counts were enumerated 24 h later. Asterisks indicate significant differences ($p < 0.05$) between samples, as determined using one-way analysis of variance (ANOVA) with Dunnett's multiple comparisons tests.



efficiency for NleB1^{EHEC} were 2.5-, 2.2- and 5.4-fold better than those of SseK1^{wt} (Fig. 4b and Table S5†).

We then performed enzyme kinetics assays on mutants S286I/N/Y^{SseK1} and N302I/S/Y^{SseK2}. As found for SseK2^{wt} on DR3^{DD}, S286N^{SseK1} was also inactive on DR3^{DD} (Fig. 4a, right panel). The other mutants displayed different degrees of initial velocities. Although the initial velocity for the mutants S286I^{SseK1} and N302I/S^{SseK2} was approximately half that of NleB1^{EHEC} at 140 μ M DR3^{DD}, these mutants did not reach saturated kinetics, preventing us from determining their kinetic parameters. However, we could obtain kinetic parameters for S286Y^{SseK1} and N302Y^{SseK2} (Fig. 4a, b, Table S5†). Again, the mutation to Tyr in both enzymes provided DR3^{DD} saturation curves. The K_m s for NleB1^{EHEC} and S286Y^{SseK1} were similar while k_{cat} and catalytic efficiency were ~1.75-fold better for NleB1^{EHEC} than S286Y^{SseK1}. On the contrary, k_{cat} values were similar for NleB1^{EHEC} and N302Y^{SseK2}, differing more in K_m and catalytic efficiency (3.3- and 4.1-fold better constants for NleB1^{EHEC} than those for N302Y^{SseK2}; Table S5†). Overall, our data with DR3^{DD} are slightly more complex than the ones for FADD^{DD}, and in particular suggest that a Tyr residue in positions 284^{C²⁸⁴NleB/NleB1}, 286^{SseK1} and 302^{SseK2} is more beneficial for enzyme kinetics than a Ser, and the latter over Ile, being an Asn residue in those positions deleterious for activity.

The S286Y^{SseK1} and N302Y^{SseK2} mutants promote *Salmonella enterica* survival in macrophages

Finally, we rationalized that if Tyr286^{SseK1} and Tyr302^{SseK2} strikingly improve the kinetic and the thermodynamic parameters, these mutants might also increase the survival of *Salmonella enterica* strains in infected macrophages. To test this hypothesis, we introduced in a *Salmonella* strain lacking all SseK GTs the constructs encoding for the expression of SseK1^{wt}, SseK2^{wt}, S286Y^{SseK1} and N302Y^{SseK2}. The survival of these mutated strains was evaluated in macrophages showing that S286Y^{SseK1} and N302Y^{SseK2} improved the proliferation of this bacterium compared to the strains lacking the expression of all SseK GTs or expressing specifically either SseK1^{wt} or SseK2^{wt}. In addition, the level of proliferation reached by strains expressing S286Y^{SseK1} and N302Y^{SseK2} was highly similar to the wild type bacteria that expresses all three GTs (Fig. 5). This result again demonstrates that SseK GTs containing a Tyr residue in 286^{SseK1}, 302^{SseK2}, and potentially 289^{SseK3} are more robust enzymes that lead to bacterial proliferation in macrophages and in turn, virulence.

Conclusions

Why *Salmonella enterica* strains encode three functional NleB orthologs with a narrowed substrate selectivity is puzzling. *Salmonella enterica* differs from EHEC/EPEC *E. coli* and *C. rodentium* both in its life cycle and also in the different location of its GTs in host cells. While EHEC/EPEC *E. coli* or *C. rodentium* are extracellular pathogens, *Salmonella enterica* strains are intracellular pathogens. Furthermore, CrNleB/NleB1^{EPEC/EHEC}/SseK1 are cytoplasmic proteins, while SseK2/SseK3 are Golgi-

associated GTs.¹⁵ This provides another way of regulating the types of protein substrates being glycosylated, which for SseK3 is unique as recently reported.²² Hence, the SseK narrowed substrate selectivity together with the location-dependent glycosylation of SseK1/2/3^{wt} might endow *Salmonella enterica* strains with novel ways of hijacking host signaling pathways. However, the selection pressures, if any, driving the differing substrate selectivities among these enzymes, have yet to be investigated.

Here, we have addressed the molecular basis of this narrowed substrate selectivity, which relies on a unique second-shell residue, variable between the SseK GTs and located in the interface of the NleB/SseK-protein substrate complex. The mutation of this second-shell residue, either Ser286^{SseK1} or Asn302^{SseK2}, to Tyr^{NleB/NleB1}, leads to mutants with optimal kinetic and thermodynamic parameters. The mutants S286Y^{SseK1} and N302Y^{SseK2} become active on particular protein substrates such as FADD^{DD} and DR3^{DD}, respectively, leading potentially to mutants with a broader substrate selectivity as that of CrNleB/NleB1^{EPEC/EHEC}. This is also supported by the increase in *Salmonella* abundance in macrophages by strains expressing these mutants. These mutants promote binding and catalysis, likely because the binding of this second-shell residue surrounding residues is coupled to the stability of the interaction between the acceptor Arg with the catalytic base residue. Therefore, the identity of the second-shell residue finely tunes protein substrate selectivity and, in turn, glycosylation, and might explain whether GT substrate selectivity is narrow or broad.

Promiscuous GTs act on multiple protein substrates and are found in all animal kingdoms.⁴ Several GTs mechanisms have been discovered by combining X-ray crystallography experiments with other biophysical and biochemical techniques. Initiating GTs such as POFUT1/POGLUT1 (also called Rumi) and POFUT2, require folded EGF and TSR repeats, respectively. These GTs share in common that the EGF and TSR repeats are tethered by direct hydrogen bonds, and require EGF and TSR repeats containing minimal consensus sequences that encompass mostly variable residues located in between two cysteine residues. However, POFUT2, and to a lesser extent POFUT1, apply additional strategies to recognize many different protein substrates, leveraging the water molecules present in the interface of the complexes to recognize different repeats. In addition, POGLUT1 and POFUT2 also interact with the repeats by hydrophobic interactions.^{31–33} Other initiating GTs, such as OGT and the large family of GalNAc-T isoenzymes (20 in humans) recognize mostly unfolded extended and compact structures of the peptide acceptor substrates, respectively, by establishing hydrogen bonds. Thus, for example, while for OGT a proline (Pro) residue in -2 (promoting the extended conformation) is required for optimal glycosylation,³⁴ a Pro-X-Pro motif (promoting the compact conformation) contiguous to the preceding Ser/Thr residue usually favors glycosylation.³⁵ In addition, GalNAc-Ts contain a flexible linker located in between the catalytic and the lectin domains, and a flexible loop that provides them with different behaviors due to their dissimilar amino acid sequences. While the flexible linker is behind the



dynamics of these isoenzymes and the location of the GalNAc-binding site in the lectin domain,^{36,37} the flexible loop controls the catalytic cycle and is also behind the recognition of protein substrates.^{38,39} Together, both the flexible linker and loop determine whether several GalNAc-T isoenzymes are highly specific for particular protein substrates.^{38,40} The SseK GTs have evolved different features at molecular level to selectively recognize particular protein substrates. These features rely on variable residues located in the HLH domain and mostly in a particular variable second-shell residue with respect to the conserved Tyr284^{NleB/NleB1} residue.

In conclusion, and to our knowledge, this is a unique example of restoring the activity of enzymes that are inactive on particular protein substrates by a single site-directed mutagenesis. Overall, our finding provides the molecular basis of the differences between NleB/SseK GTs substrate selectivity and offers clues on the molecular pathogenesis of enteropathogens.

Data availability

Data are available from the corresponding authors upon reasonable request.

Author contribution

R. H.-G., J. A. and T. H. performed the bioinformatic analysis of the enzymes and R. H.-G. selected the positions for site-directed mutagenesis experiments. A. G.-G. purified the enzymes and characterized them by enzyme kinetics and ITC experiments. T. H. and J. A. performed the molecular dynamics simulations. S. E. Q. and C. Z. performed the macrophage experiments and made the *Salmonella* mutants. R. H.-G. wrote the article with the contribution of J. A. and P. R. H. All authors read and approved the final manuscript.

Conflicts of interest

The authors declare no competing interests.

Acknowledgements

We thank ARAID, the Spanish Ministry of Science, Innovation and Universities (BFU2016-75633-P and PID2019-105451GB-I00 to R. H.-G., and PID2019-109395GB-I00 to J. A.), and Gobierno de Aragón (E34_R17 and LMP58_18 to R. H.-G.) with FEDER (2014–2020) funds for “Building Europe from Aragón” for financial support. A. G.-G. thanks Gobierno de Aragón for a predoctoral fellowship. J. A. also acknowledges funding support from the Biotechnology and Biological Sciences Research Council (BBSRC; BB/P010660/1). T. H. acknowledges a BBSRC DTP studentship (BB/M011216/1). Support from the Universidad de Sevilla (Acciones Especiales del VI Plan Propio de Investigación y Transferencia) is also acknowledged. The project described was supported by grant numbers AI127973 and AI153202 from the National Institute of Allergy and Infectious Diseases (NIAID) and by the National Institute of General Medical Sciences (NIGMS) of the National Institutes of Health under award

number P20GM130448 to P. R. H. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health.

References

- R. A. Flynn, K. Pedram, S. A. Malaker, P. J. Batista, B. A. H. Smith, A. G. Johnson, B. M. George, K. Majzoub, P. W. Villalta, J. E. Carette and C. R. Bertozzi, *Cell*, 2021, **184**, 3109–3124 e3122.
- A. Biswas and M. Thattai, *Biochem. Soc. Trans.*, 2020, **48**, 891–900.
- K. T. Schjoldager, Y. Narimatsu, H. J. Joshi and H. Clausen, *Nat. Rev. Mol. Cell Biol.*, 2020, **21**, 729–749.
- H. J. Joshi, Y. Narimatsu, K. T. Schjoldager, H. L. P. Tytgat, M. Aebi, H. Clausen and A. Halim, *Cell*, 2018, **172**, 632–632 e632.
- X. Pan, J. Luo and S. Li, *Front. Cell. Infect. Microbiol.*, 2020, **10**, 185.
- J. Lassak, E. C. Keilhauer, M. Furst, K. Wuichet, J. Godeke, A. L. Starosta, J. M. Chen, L. Sogaard-Andersen, J. Rohr, D. N. Wilson, S. Haussler, M. Mann and K. Jung, *Nat. Chem. Biol.*, 2015, **11**, 266–270.
- X. Gao, X. Wang, T. H. Pham, L. A. Feuerbacher, M. L. Lubos, M. Huang, R. Olsen, A. Mushegian, C. Slawson and P. R. Hardwidge, *Cell Host Microbe*, 2013, **13**, 87–99.
- J. S. Pearson, C. Giogha, S. Y. Ong, C. L. Kennedy, M. Kelly, K. S. Robinson, T. W. Lung, A. Mansell, P. Riedmaier, C. V. Oates, A. Zaid, S. Muhlen, V. F. Crepin, O. Marches, C. S. Ang, N. A. Williamson, L. A. O'Reilly, A. Bankovacki, U. Nachbur, G. Infusini, A. I. Webb, J. Silke, A. Strasser, G. Frankel and E. L. Hartland, *Nature*, 2013, **501**, 247–251.
- S. Li, L. Zhang, Q. Yao, L. Li, N. Dong, J. Rong, W. Gao, X. Ding, L. Sun, X. Chen, S. Chen and F. Shao, *Nature*, 2013, **501**, 242–246.
- S. El Qaidi, K. Chen, A. Halim, L. Siukstaite, C. Rueter, R. Hurtado-Guerrero, H. Clausen and P. R. Hardwidge, *J. Biol. Chem.*, 2017, **292**, 11423–11430.
- S. El Qaidi, N. E. Scott, M. P. Hays, B. V. Geisbrecht, S. Watkins and P. R. Hardwidge, *Sci. Rep.*, 2020, **10**, 1073.
- S. El Qaidi, N. E. Scott and P. R. Hardwidge, *Sci. Rep.*, 2021, **11**, 3834.
- V. Lombard, H. Golaconda Ramulu, E. Drula, P. M. Coutinho and B. Henrissat, *Nucleic Acids Res.*, 2014, **42**, D490–D495.
- C. Giogha, N. E. Scott, T. Wong Fok Lung, G. L. Pollock, M. Harper, E. D. Goddard-Borger, J. S. Pearson and E. L. Hartland, *PLoS Pathog.*, 2021, **17**, e1009658.
- J. L. Araujo-Garrido, J. Bernal-Bayard and F. Ramos-Morales, *Microorganisms*, 2020, **8**, 1–23.
- D. Esposito, R. A. Gunster, L. Martino, K. El Omari, A. Wagner, T. L. M. Thurston and K. Rittinger, *J. Biol. Chem.*, 2018, **293**, 5064–5078.
- J. B. Park, Y. H. Kim, Y. Yoo, J. Kim, S. H. Jun, J. W. Cho, S. El Qaidi, S. Walpole, S. Monaco, A. A. Garcia-Garcia, M. Wu, M. P. Hays, R. Hurtado-Guerrero, J. Angulo, P. R. Hardwidge, J. S. Shin and H. S. Cho, *Nat. Commun.*, 2018, **9**, 4283.



18 J. P. M. Newson, N. E. Scott, I. Yeuk Wah Chung, T. Wong Fok Lung, C. Giogha, J. Gan, N. Wang, R. A. Strugnell, N. F. Brown, M. Cygler, J. S. Pearson and E. L. Hartland, *Mol. Cell. Proteomics*, 2019, **18**, 1138–1156.

19 J. Ding, X. Pan, L. Du, Q. Yao, J. Xue, H. Yao, D. C. Wang, S. Li and F. Shao, *Mol. Cell*, 2019, **74**, 922–935 e926.

20 X. Gao, T. H. Pham, L. A. Feuerbacher, K. Chen, M. P. Hays, G. Singh, C. Rueter, R. Hurtado-Guerrero and P. R. Hardwidge, *J. Biol. Chem.*, 2016, **291**, 18232–18238.

21 C. Xu, X. Liu, H. Zha, S. Fan, D. Zhang, S. Li and W. Xiao, *PLoS Pathog.*, 2018, **14**, e1007259.

22 J. Gan, N. E. Scott, J. P. M. Newson, R. R. Wibawa, T. Wong Fok Lung, G. L. Pollock, G. Z. Ng, I. van Driel, J. S. Pearson, E. L. Hartland and C. Giogha, *Front. Cell. Infect. Microbiol.*, 2020, **10**, 419.

23 R. Krafczyk, J. Macosek, P. K. A. Jagtap, D. Gast, S. Wunder, P. Mitra, A. K. Jha, J. Rohr, A. Hoffmann-Roder, K. Jung, J. Hennig and J. Lassak, *mBio*, 2017, **8**, e01412-17.

24 C. I. Chen, J. J. Keusch, D. Klein, D. Hess, J. Hofsteenge and H. Gut, *EMBO J.*, 2012, **31**, 3183–3197.

25 M. de Las Rivas, E. J. Paul Daniel, Y. Narimatsu, I. Companon, K. Kato, P. Hermosilla, A. Thureau, L. Ceballos-Laita, H. Coelho, P. Bernado, F. Marcelo, L. Hansen, R. Maeda, A. Lostao, F. Corzana, H. Clausen, T. A. Gerken and R. Hurtado-Guerrero, *Nat. Chem. Biol.*, 2020, **16**, 351–360.

26 A. Naegeli, G. Michaud, M. Schubert, C. W. Lin, C. Lizak, T. Darbre, J. L. Reymond and M. Aebi, *J. Biol. Chem.*, 2014, **289**, 24521–24532.

27 W. Kightlinger, L. Lin, M. Rosztoczy, W. Li, M. P. DeLisa, M. Mrksich and M. C. Jewett, *Nat. Chem. Biol.*, 2018, **14**, 627–635.

28 E. Lira-Navarrete, J. Iglesias-Fernandez, W. F. Zandberg, I. Companon, Y. Kong, F. Corzana, B. M. Pinto, H. Clausen, J. M. Peregrina, D. J. Vocadlo, C. Rovira and R. Hurtado-Guerrero, *Angew. Chem., Int. Ed. Engl.*, 2014, **53**, 8206–8210.

29 B. Ramakrishnan, E. Boeggeman and P. K. Qasba, *Biochem. Biophys. Res. Commun.*, 2002, **291**, 1113–1118.

30 M. de Las Rivas, H. Coelho, A. Diniz, E. Lira-Navarrete, I. Companon, J. Jimenez-Barbero, K. T. Schjoldager, E. P. Bennett, S. Y. Vakhrushev, H. Clausen, F. Corzana, F. Marcelo and R. Hurtado-Guerrero, *Chemistry*, 2018, **24**, 8382–8392.

31 Z. Li, K. Han, J. E. Pak, M. Satkunarajah, D. Zhou and J. M. Rini, *Nat. Chem. Biol.*, 2017, **13**, 757–763.

32 H. Yu, H. Takeuchi, M. Takeuchi, Q. Liu, J. Kantharia, R. S. Haltiwanger and H. Li, *Nat. Chem. Biol.*, 2016, **12**, 735–740.

33 J. Valero-González, C. Leonhard-Melief, E. Lira-Navarrete, G. Jiménez-Osés, C. Hernández-Ruiz, M. C. Pallarés, I. Yruela, D. Vasudevan, A. Lostao, F. Corzana, H. Takeuchi, R. S. Haltiwanger and R. Hurtado-Guerrero, *Nat. Chem. Biol.*, 2016, **12**, 240–246.

34 S. Pathak, J. Alonso, M. Schimpl, K. Rafie, D. E. Blair, V. S. Borodkin, A. W. Schüttelkopf, O. Albarbarawi and D. M. F. van Aalten, *Nat. Struct. Mol. Biol.*, 2015, **22**, 744–750.

35 M. de las Rivas, E. Lira-Navarrete, T. A. Gerken and R. Hurtado-Guerrero, *Curr. Opin. Struct. Biol.*, 2019, **56**, 87–96.

36 E. Lira-Navarrete, M. de las Rivas, I. Compañón, M. C. Pallarés, Y. Kong, J. Iglesias-Fernández, G. J. L. Bernardes, J. M. Peregrina, C. Rovira, P. Bernadó, P. Bruscolini, H. Clausen, A. Lostao, F. Corzana and R. Hurtado-Guerrero, *Nat. Commun.*, 2015, **6**, 6937.

37 M. de las Rivas, E. Lira-Navarrete, E. J. P. Daniel, I. Compañón, H. Coelho, A. Diniz, J. Jiménez-Barbero, J. M. Peregrina, H. Clausen, F. Corzana, F. Marcelo, G. Jiménez-Osés, T. A. Gerken and R. Hurtado-Guerrero, *Nat. Commun.*, 2017, **8**, 1959.

38 M. de las Rivas, E. J. Paul Daniel, H. Coelho, E. Lira-Navarrete, L. Raich, I. Compañón, A. Diniz, L. Lagartera, J. Jiménez-Barbero, H. Clausen, C. Rovira, F. Marcelo, F. Corzana, T. A. Gerken and R. Hurtado-Guerrero, *ACS Cent. Sci.*, 2018, **4**, 1274–1290.

39 M. de las Rivas, H. Coelho, A. Diniz, E. Lira-Navarrete, I. Compañón, J. Jiménez-Barbero, K. T. Schjoldager, E. P. Bennett, S. Y. Vakhrushev, H. Clausen, F. Corzana, F. Marcelo and R. Hurtado-Guerrero, *Chem. - Eur. J.*, 2018, **24**, 8382–8392.

40 M. de las Rivas, E. J. Paul Daniel, Y. Narimatsu, I. Compañón, K. Kato, P. Hermosilla, A. Thureau, L. Ceballos-Laita, H. Coelho, P. Bernadó, F. Marcelo, L. Hansen, R. Maeda, A. Lostao, F. Corzana, H. Clausen, T. A. Gerken and R. Hurtado-Guerrero, *Nat. Chem. Biol.*, 2020, **16**, 351–360.

